Loading
A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumour Resection is a phase 3 interventional study registered as NCT07128199, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumour Resection (REZILIENT4). Planned enrolment is 360 participants (estimated). The study started in 2025-12-22 and primary completion is expected in 2029-10-01. No results have been posted on ClinicalTrials.gov.
Shares Taiho Oncology (Otsuka), Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Zipalertinib, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.